CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer

BACKGROUND: There was much hard work to study the trastuzumab resistance in HER2-positive gastric cancer (GC), but the information which would reveal this abstruse mechanism is little. In this study, we aimed to investigate the roles of tumor cell-derived CCL2 on trastuzumab resistance and overcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Weilin, Wang, Xi, Wang, Daohan, Lu, Li, Lin, Hai, Zhang, Zhaoxiong, Jia, Yangpu, Nie, Xinyang, Liu, Tong, Fu, Weihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295658/
https://www.ncbi.nlm.nih.gov/pubmed/35851310
http://dx.doi.org/10.1136/jitc-2022-005063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295658/
https://www.ncbi.nlm.nih.gov/pubmed/35851310
http://dx.doi.org/10.1136/jitc-2022-005063

Ejemplares similares